GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2021, and provided an operational update. “We enter the final stretch of LUMEVOQ’s registration phase in a very strong financial position,” commented Bern